NewAmsterdam Pharma Company NAMS Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by NewAmsterdam Pharma Company in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about NewAmsterdam Pharma Company's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is NewAmsterdam Pharma Company's additional paid-in capital?
- NewAmsterdam Pharma Company (NAMS) reported additional paid-in capital of $1.46B in Q1 2026.
- How has NewAmsterdam Pharma Company's additional paid-in capital changed year-over-year?
- NewAmsterdam Pharma Company's additional paid-in capital increased by 7.4% year-over-year, from $1.36B to $1.46B.
- What is the long-term trend for NewAmsterdam Pharma Company's additional paid-in capital?
- Over 3 years (2022 to 2025), NewAmsterdam Pharma Company's additional paid-in capital has grown at a 36.9% compound annual growth rate (CAGR), from $555.63M to $1.43B.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.